Company intelligence / Profile preview

Angioslide

Edina, Minnesota, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~7
Development stage: Commercial

Overview

Angioslide has developed the PROTEUS device family using its proprietary ECA technology. The device combines standard balloon angioplasty with an integrated mechanism to capture and remove embolic debris during procedures. It has received both FDA clearance for lower limb use in the US and CE Mark approval in Europe. Multi-center clinical trials have demonstrated its efficacy for removing embolic particles while functioning as a PTA balloon. The product line includes above-the-knee and below-the-knee platforms.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

PROTEUS

Commercial

Indications: Peripheral arterial disease

Beyond the preview

Go deeper on Angioslide.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angioslide.

Explore the full profile